Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

  • Jesús Troya,
  • Pablo Ryan,
  • Esteban Ribera,
  • Daniel Podzamczer,
  • Victor Hontañón,
  • Jose Alberto Terrón,
  • Vicente Boix,
  • Santiago Moreno,
  • Pilar Barrufet,
  • Manuel Castaño,
  • Ana Carrero,
  • María José Galindo,
  • Ignacio Suárez-Lozano,
  • Hernando Knobel,
  • Miguel Raffo,
  • Javier Solís,
  • María Yllescas,
  • Herminia Esteban,
  • Juan González-García,
  • Juan Berenguer,
  • Arkaitz Imaz,
  •  [ ... ],
  • GESIDA-8314 Study Group
  • [ view all ]
  • [ view less ]

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

  • Jesús Troya, 
  • Pablo Ryan, 
  • Esteban Ribera, 
  • Daniel Podzamczer, 
  • Victor Hontañón, 
  • Jose Alberto Terrón, 
  • Vicente Boix, 
  • Santiago Moreno, 
  • Pilar Barrufet, 
  • Manuel Castaño
PLOS
x

The affiliation of the author Juan Berenguer is incorrect. The correct affiliation is: Hospital Universitario Gregorio Marañón, Madrid, Spain.

Reference

  1. 1. Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, et al. (2016) Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE 11(10): e0164455. pmid:27727331